Opinion
Video
Author(s):
Focusing on castration-resistant prostate cancer, the panel reviews treatment options for patients with metastatic and nonmetastatic disease.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Long-term data support radium-223 safety in mCRPC
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025
PEACE-3 data for radium-223/enzalutamide published in Annals of Oncology
Dr. Murphy on increasing diversity in cancer clinical trials
ORIC-944 shows promise in combination with AR inhibitors in mCRPC
FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer
Lower-dose abiraterone offers viable alternative to standard-dose for mCRPC
Survey: New NMIBC treatments face slow uptake
RCT compares platinum/5-FU, platinum/paclitaxel in high-risk penile cancer